drugset / Trial / NCT02877927

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

NCT02877927

Phase 3 Completed 735 enrolled Paratek Pharmaceuticals Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.

Timeline

Start
2016-08
Primary completion
2017-05-26
Completion
2017-06-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 600 mg Oral
Subject Omadacycline Small molecule 300 mg Oral